Io Therapeutics (United States)

Recent papers from Io Therapeutics (United States)

1. Discovery of a Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK) Inhibitor Suitable for Clinical ProgressionJournal of Medicinal Chemistry · 2026
2. Critical Roles of O ‐Acetylation Revealed by Synthetic Trisaccharide Antigens for a Broad‐Spectrum Anti‐ Salmonella VaccineAdvanced Science · 2026
3. Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paperNPP—Digital Psychiatry and Neuroscience · 2026
4. Discovery and development of a bispecific antibody for the treatment of hemophiliaProceedings of the National Academy of Sciences · 2026
5. Combining advanced 3D spheroid-based skin models with deep-learning-based image analysis enables in-depth investigation of keratinocyte differentiation and barrier functionFrontiers in Bioengineering and Biotechnology · 2026
6. Cannabidiol and neural correlates of threat anticipation in alcohol use disorderPsychopharmacology · 2026
7. 64 GPR65 is a Novel Therapeutic Target Associated with Immune Exhaustion in Clear Cell Renal Cell CarcinomaThe Oncologist · 2026
8. Genome-wide CRISPR screens map synthetic lethal interactions across recurrent cancer driver alterationsCell Reports · 2026
9. Parturition attenuates endothelial senescence to resist nitrosative stress-induced heart failure with preserved ejection fraction in miceCardiovascular Diabetology · 2026
10. Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activatorJournal of Experimental & Clinical Cancer Research · 2026
11. Antiviral targets in the prevention and treatment of measlesCurrent Opinion in Infectious Diseases · 2026
12. Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based TherapeuticsCancers · 2026
13. Efficacy, safety, and pharmacokinetics of pumecitinib nasal spray for moderate-to-severe seasonal allergic rhinitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Regional Health - Western Pacific · 2026
14. Molecular Glue and Phosphorylation-Dependent 14-3-3 Recruitment to p53 with an Engineered Interaction CassetteACS Chemical Biology · 2026
15. Enhanced Sampling and Ligandability Assessment to Expand the Repertoire of Potentially Druggable Cryptic PocketsJournal of the American Chemical Society · 2026
16. Design, Synthesis, and Antitumor Activity Evaluation of Novel Dual A2A/A2B Adenosine Receptor AntagonistsJournal of Medicinal Chemistry · 2026
17. Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.Clinical Cancer Research · 2026
18. Combined Plasmid Redesign and Transfection Optimization Significantly Increases Upstream AAV Titers While Maintaining Vector Quality and In Vivo PotencyMicroorganisms · 2026
19. Topical MSC-Derived Extracellular Vesicles Accelerate Healing of Second-Degree Burns: A Case ReportJournal of Burn Care & Research · 2026
20. Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic MalignanciesBlood · 2026